About Clarke Atwell
Clarke Atwell is a co-founder and chief operating officer at Claris Biotherapeutics.
Form D filings also name Clarke Atwell as a director at Synedgen.
Clarke Atwell first appears on SEC filings in 2011.
Experience
This experience comes from Clarke Atwell's profile and from SEC filings. For roles taken from filings, the years are when the filings name Clarke Atwell in the role, so the role may have started earlier or lasted longer.
Claris Biotherapeutics, Inc. Current
Co-Founder and Chief Operating Officer
CEO and President (2018 – Present)
2018 – Present · Half Moon Bay, CA
Develops eye treatments for people with sight-threatening corneal diseases.
LB
Lux Biosciences
COO and Co-Founder
2005 – 2014
EP
Enzon Pharmaceuticals
Vice President Marketing and Sales
2002 – 2005
RP
Roche Pharmaceuticals
Director
1999 – 2001
ME
Merck
MIR Coordinator
1992 – 1996
Key Colleagues at Startups
The people Clarke Atwell works with at each company, as listed on that company's latest Form D.
Claris Biotherapeutics, Inc. · Form D/A, Aug 12, 2026
Brian Baum
Chief Commercial Officer
MF
Meredith Fisher
Director
RD
Reza Dana
Director
Stephen Brady
President and Chief Executive Officer, director
Henry Rath
Chief Business Officer
KH
Kenneth Harrison
Director
MH
Matt Hobson
Director
MD
Michael Dybbs
Director
MR
Maha Radhakrishnan
Director
Susan Orr
Chief Medical Officer
MG
Marc de Garidel
Director
Synedgen, Inc. · Form D, Apr 27, 2016
PG
Paul Grint
Director
SB
Shenda Baker
President and director
KG
Kenton Gregory
Director
LS
Larry Shapiro
Director
DO
Diane Olmstead
Director
AM
Andrew Miller
Director
WW
William Wiesmann
Executive officer and director